THEOCLEAR-200
Clinical safety rating
cautionComprehensive clinical and safety monograph for THEOCLEAR-200 (THEOCLEAR-200).
Theophylline is a methylxanthine that inhibits phosphodiesterase, increasing intracellular cAMP levels, leading to bronchodilation. It also acts as an adenosine receptor antagonist and may enhance diaphragmatic contractility.
| Metabolism | Hepatic via CYP1A2, CYP2E1, and CYP3A4. Follows Michaelis-Menten kinetics with dose-dependent metabolism. |
| Excretion | Renal: ~10% unchanged; Hepatic metabolism (CYP1A2, CYP3A4) accounts for ~90% of elimination; metabolites (caffeine, 3-methylxanthine, 1-methyluric acid) excreted renally. Fecal excretion negligible. |
| Half-life | Terminal elimination half-life: ~8 hours (range 3–12 hours) in adults; prolonged in hepatic impairment, heart failure, COPD, and neonates. Significantly shorter in smokers (4–6 hours). |
| Protein binding | ~40% bound, primarily to albumin. |
| Volume of Distribution | 0.3–0.7 L/kg; approx. 0.45 L/kg in adults. Increased Vd in premature infants, cirrhosis, and CHF. Distributes freely into breast milk and across placenta. |
| Bioavailability | Oral: 96% (nearly complete). Rectal: variable (70–90%). Intravenous: 100%. |
| Onset of Action | Oral immediate-release: 30–60 minutes. Intravenous: within minutes. Rectal: similar to oral. Peak effect correlates with serum concentration. |
| Duration of Action | Oral immediate-release: 6–8 hours. Extended-release formulations: 12–24 hours. Bronchodilation persists as long as serum levels remain in therapeutic range (10–20 mcg/mL). |
| Molecular Weight | 180.16 |
Theophylline 200 mg orally every 6 hours (extended-release) or as directed by serum theophylline concentrations. Usual adult target: 400-600 mg/day.
| Dosage form | TABLET |
| Renal impairment | No specific GFR-based dose adjustments are recommended; however, monitor serum theophylline concentrations in patients with renal impairment as clearance may be reduced. |
| Liver impairment | Child-Pugh Class A: reduce dose by 50%. Child-Pugh Class B: reduce dose by 75%. Child-Pugh Class C: avoid use or use with extreme caution; monitor serum levels frequently. Dose adjustments should be guided by serum theophylline concentrations. |
| Pediatric use | Initial dose: 5 mg/kg orally every 6 hours (immediate-release) or 10-15 mg/kg/day divided every 12 hours (extended-release). Titrate based on serum theophylline levels (target 5-15 mcg/mL). Maximum dose: 16 mg/kg/day up to 400 mg/day for children 1-9 years; 16 mg/kg/day up to 600 mg/day for children 9-16 years. |
| Geriatric use | Start at lowest effective dose (e.g., 200 mg once daily) and titrate slowly. Monitor serum theophylline concentrations closely due to reduced clearance in elderly. Target serum level: 5-10 mcg/mL. |
| 1st trimester | Theophylline crosses the placenta. Limited human data; avoid unless benefit outweighs risk. Use lowest effective dose. |
| 2nd trimester | Limited human data; risk of fetal tachycardia and irritability. Use only if clearly needed. |
| 3rd trimester | Neonatal withdrawal symptoms (jitteriness, tachycardia) may occur. Use only if clearly needed; consider tapering before delivery. |
Clinical note
Comprehensive clinical and safety monograph for THEOCLEAR-200 (THEOCLEAR-200).
| Placental transfer | Theophylline crosses the placenta freely; fetal serum concentrations approximate maternal levels. |
| Breastfeeding | Theophylline is excreted into breast milk in small amounts (approx. 1% of maternal dose). Monitor infant for irritability and insomnia. Generally considered compatible with breastfeeding if used with caution. |
| Lactation Rating | L3 (Moderately Safe) |
| Teratogenic Risk | FDA Pregnancy Category C. First trimester: Crosses placenta; limited data suggest no major malformations but fetal tachycardia and jitteriness reported. Second and third trimesters: Risk of neonatal apnea, hypoglycemia, and hypocalcemia due to beta-adrenergic stimulation. Avoid during labor due to risk of maternal tachycardia and fetal distress. |
| Fetal Monitoring | Monitor maternal heart rate, blood pressure, and serum theophylline levels (therapeutic range 10-20 mcg/mL). Fetal monitoring including heart rate and growth ultrasound. Assess for maternal signs of toxicity (tachycardia, arrhythmias, seizures). |
| Fertility Effects | Limited data; no established adverse effects on fertility in humans. Animal studies show no impairment at clinically relevant doses. |
■ FDA Black Box Warning
None
| Serious Effects |
Hypersensitivity to theophylline or any componentActive peptic ulcer diseaseSeizure disorder (unless adequately controlled)
| Precautions | Narrow therapeutic index; serum levels must be monitored to avoid toxicity., Use with caution in patients with peptic ulcer, seizure disorders, or cardiac arrhythmias., Coadministration with drugs that affect CYP1A2 (e.g., cimetidine, fluoroquinolones, macrolides) can alter theophylline clearance., May cause tachycardia, palpitations, and central nervous system stimulation. |
| Food/Dietary | Avoid excessive caffeine intake (coffee, tea, chocolate, cola) as it can potentiate side effects. Food does not significantly alter absorption, but take with food if gastrointestinal upset occurs. Charcoal-broiled foods may increase metabolism; maintain consistent intake. |
| Clinical Pearls | Theophylline has a narrow therapeutic index (5-15 mcg/mL); levels >20 mcg/mL increase toxicity risk. Use with caution in patients with hepatic impairment, heart failure, or fever, as clearance is reduced. Cimetidine, ciprofloxacin, and macrolides increase theophylline levels; monitor levels and adjust dose. Smoking induces metabolism; require higher doses. Consider drug interactions with CYP1A2 inhibitors/inducers. Serum theophylline levels should be monitored at steady state and with any change in medication or condition. |
| Patient Advice | Take THEOCLEAR-200 exactly as prescribed; do not change dose without consulting your doctor. · Do not crush or chew sustained-release tablets; swallow whole. · Avoid large amounts of caffeine (coffee, tea, chocolate, cola) as it may increase side effects. · Inform your doctor if you experience nausea, vomiting, insomnia, tremors, or rapid heartbeat. · Do not smoke or start/stop smoking without telling your doctor, as it affects theophylline levels. · Keep all appointments for blood tests to monitor theophylline levels. · Store at room temperature away from moisture and heat. |
Loading safety data…